Montelukast Voor Pediatrische Patiënten Van 2 Tot 5 Jaar Accord (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor type 1 (CysLT1). This inhibition prevents leukotrienes from causing bronchoconstriction, airway swelling, and mucus production, thereby improving breathing and decreasing allergic inflammation.

The appropriate dose for each child is determined by the prescribing healthcare professional based on the child’s age, weight, and clinical condition. Parents and caregivers should follow the prescriber’s instructions and not adjust the dose on their own.

Montelukast is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during breastfeeding if the prescriber judges the benefit outweighs any potential risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast is a leukotriene receptor antagonist that targets a different inflammatory pathway than inhaled corticosteroids, which act on a broad range of inflammatory mediators. Montelukast is often used as an add‑on therapy or for patients who cannot tolerate steroids, but it does not replace the anti‑inflammatory effect of inhaled corticosteroids in moderate‑to‑severe asthma.

Store Montelukast tablets or oral suspension at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and discard any medication that appears discoloured or past its expiry date.

Montelukast is taken orally, usually once daily in the evening. The tablet can be swallowed whole or, if a chewable or liquid form is supplied, administered according to the prescriber’s instructions. It should be taken with or without food as directed.

Serious risks include rare allergic reactions such as angioedema or anaphylaxis, neuropsychiatric events like mood changes or suicidal thoughts, and severe skin reactions such as Stevens‑Johnson syndrome. Caregivers should seek immediate medical attention if any of these symptoms occur.

Montelukast should not be used in children younger than two years, in patients with known hypersensitivity to montelukast or any component of the formulation, and it should be avoided in individuals with a history of severe allergic reactions to leukotriene‑modifying agents.